Sagimet Biosciences Inc. - Series ANASDAQ: SGMT

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Sagimet Biosciences Inc. - Series A via GlobeNewswire

Summary by 6ix AI

The Compensation Committee of Sagimet Biosciences' Board of Directors approved an inducement grant of 260,700 stock options in aggregate to purchase Series A common stock, granted on August 17, 2026 to 3 newly hired employees. Sagimet is a clinical-stage biopharmaceutical company developing drugs targeting metabolic and fibrotic pathways.

Key details

  • The options were granted under the Nasdaq Rule 5635(c)(4) inducement grant exception, which covers stock awards given to new hires as an inducement to accept employment, as part of each person's employment compensation.
  • The exercise price equals the closing price of Sagimet's Series A common stock on the Nasdaq Global Market on August 17, 2026.
  • The options have a ten-year term and vest over four years: 25% of the shares underlying each option vest on the one-year anniversary of the vesting commencement date (based on the employee's start date), and the rest vest monthly over the following 36 months.

What’s still pending

  • Vesting is subject to each individual's continued service with Sagimet through the applicable vesting dates.

6ix AI wrote this summary from the release below and checked it against the release.

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.

The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on August 17, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual’s continued service with Sagimet through the applicable vesting dates.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

Sagimet Biosciences Inc. - Series A on 6ix

Story so far

Earlier from Sagimet Biosciences Inc. - Series A

Later from Sagimet Biosciences Inc. - Series A

All Sagimet Biosciences Inc. - Series A news releases